Owkin is a medical A.I. company created in 2016 that develops a federated learning A.I. platform to help pharmaceutical companies discover new drugs. Owkin has collaborated with Amgen to demonstrate the ability of A.I. to improve cardiovascular prediction. Owkin was founded in 2016, by Gilles Wainrib, a professor of Artificial Intelligence, and Thomas Clozel, a clinical research doctor and son of Jean-Paul and Martine Clozel founders of Swiss biotech Actelion. Fund Raising Valuation Owkin has raised over $255 million and became a ‘unicorn’ – a startup valued at more than $1 billion – in November 2021 through a $180 million investment from French biopharma company Sanofi.